ijms-logo

Journal Browser

Journal Browser

Cancer Diagnosis and Treatment: Exploring Molecular Research

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 959

Special Issue Editor


E-Mail Website
Guest Editor
Department of Laboratory Medicine, Chiba University Hospital, Chiba, Japan
Interests: cancer; clinical laboratiry; molecilar science; rare diases; ribosome

Special Issue Information

Dear Colleagues,

The new functions of transcription, splicing regulation, translation, and ribosomal control mechanisms are considered to be the therapeutic targets of cancer. These mechanisms are acquired and retained through evolution.

The developmental regulation of these cellular events and its induced RNA translation control are expected to introduce new possibilities for biological and medical applications in cancer research. There is also a report that the disruption of these molecular regulators can induce cancer as well as neural development disorders. There is no doubt that a greater understanding of the transcription, splicing regulation, associated RNA control, and translation with ribosomal synthesis mechanisms will help to advance cancer diagnosis and treatment.

Specific topics covered in this Special Issue include (but are not limited to) the following:

  • Alteration of gene transcription, splicing, ribosomal expression in cancer development;
  • Bio-targets and agents of novel mechanisms in gene transcription, splicing, ribosomal expression for cancer treatment;
  • Detection and screening of cancer;
  • Cellular research and biomarkers for molecular targets of cancer;
  • Epigenetics in cancer.

Dr. Kazuyuki Matsushita
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer diagnosis
  • gene transcription
  • detection and screening of cancer
  • cancer epigenetics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2336 KiB  
Article
Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer
by Natsuko Sasajima, Makoto Sumazaki, Yoko Oshima, Masaaki Ito, Satoshi Yajima, Hirotaka Takizawa, Hao Wang, Shu-Yang Li, Bo-Shi Zhang, Yoichi Yoshida, Takaki Hiwasa and Hideaki Shimada
Int. J. Mol. Sci. 2024, 25(10), 5470; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms25105470 - 17 May 2024
Viewed by 572
Abstract
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer [...] Read more.
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer. Full article
(This article belongs to the Special Issue Cancer Diagnosis and Treatment: Exploring Molecular Research)
Show Figures

Figure 1

Back to TopTop